Acne 

Actinic Keratosis 

Aesthetics

Allergy

Atopic Dermatitis 

BPDCN

COVID-19

Diabetes 

Dry Cracked Skin

Examining Nature-Based Skincare

Fibroids

Hidradentitis Suppurativa

Impetigo

Inflamed Skin

Melasma

Pediatric Dermatology

Pigmentary Disorders 

Precision Medicine and Biologics

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer

Surgery

Vitiligo

Women's Health

Wound Care

News

Device Technology

Drug Watch

Legal

Lifestyle

NP and PA

Practice Management 

Media

2 Minute Drill

Around the Practice

Between The Lines

Case Based Peer Perspective

Dermview

Dermview: Vitiligo

Editorial Board News

Expert Interviews

Expert Perspectives

Frontline Forum

Inside the Clinic

Medical World News

Podcasts

Readout360

Recognize and Refer

Viewpoints

Webinars

Conferences

Conference Coverage

Conference Listing

Publication

Dermatology Times

CME/CE

Resources

Image IQ

Interactive Tools

Job Board

Partnerships

Polls

Editorial Board

Subscribe

Print Subscription

eNewsletter

Articles

Researchers say adolescents and young adults using the dermocosmetic product experienced improvements in their acne and quality of life.

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho.

In this week’s Pointers with Dr Portela, the 208SkinDoc picks his top products for repairing sun-damaged skin. 

Pointers With Portela: Sun Damage Repair Products 

The robotic device was previously cleared to treat patients' full abdomen and flanks.



EON Gains FDA Clearance for Back and Thighs

Researchers investigated the injection’s impact on the upper face.

Botulinum Toxin Type A Unparallel Improvements to Skin Quality

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Anti-Aging

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

clinical

Clinical

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

Nonsteroidal Topical Therapies

Research suggests that as metal allergies and implants grow in frequency, some patients may need to consult a dermatologist for treatment. 

Metal Implants Can Lead to Allergic Contact Dermatitis

A recent phase 2 study revealed that the gel could act positively in microcystic lymphatic malformations, which currently have no FDA-approved treatments available.

QTORIN Rapamycin Gets Positive Topline Results for Rare Skin Disease Treatment

State of Skin Sensitivity Report raises awareness of the causes of skin sensitivity and its effect on the mind.  

New Aveeno Report Reveals 71% of Adults Have Sensitive Skin  

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

Select Skin Diseases are Higher in Patients with Inflammatory Bowel Disease

A healthy 14-year old boy was evaluated for an intensely pruritic shin rash that developed 2 weeks prior and had been treated with oral antibiotics for 10 days.

A Case of Shin Guard Dermatitis?

The US Food and Drug Administration has approved dupliumab (Dupixent; Sanofi and Regeron Phamaceuticals, Inc.) for the treatment of prurigo nodularis in adult patients.  Dermatology Times© spoke with dermatologists Amy Spizuoco, DO, FAOCD, a dual board-certified dermatologist and owner of True Dermatology in New York, New York and Christopher Bunick, MD. PhD, associate professor of dermatology, Yale Department of Dermatology, to discuss how they believes dupliumab will change the way dermatologists treat prurigo nodularis. 

: This is huge for us in the dermatology community, because patients who have prurigo nodularis suffer from extreme itching and skin lesions andup until now, we've not had anything that's super successful and effective, or FDA approved for the treatment of these conditions. Having dupilumab approved for patients with prurigo nodularis is going to change how I treat patients, because now I have something that is FDA approved and has proven efficacy and safety and tolerability for my patients, as opposed to just kind of, you know, throwing the kitchen sink at them, you know, topical steroids, light treatments, you know, things that aren't super effective and not FDA approved.

: Do you see a lot of patients that are just very frustrated with this condition?

Yes. All over our dermatology community and even in primary care and other specialties. We see tons of patients suffering from this condition, because it's extremely itchy and a lot of them affect their activities of daily living. They can't sleep, they're not concentrating at work, they are not concentrating in school. We see tons of patients suffering with this condition that haven't had good treatment that's effective and safe for them.

: Understood! Is there anything else you want to add?

: Just that I'm really excited that this medication is now going to be approved for our patients suffering with prurigo nodularis. We've seen its efficacy in patients with atopic dermatitis and other conditions in the allergy immunology world. So, it is nice to see that we have something that is approved and is effective for our patients suffering from extreme itch and skin lesions.

1. Study of Dupilumab for the Treatment of Patients with Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2). ClinicalTrials.gov identifier: NCT04202679. Updated September 28, 2022. Accessed September 28, 2022.

https://clinicaltrials.gov/ct2/show/NCT04202679?term=PRIME2&cond=Prurigo+Nodularis&draw=2&rank=

2. Study of Dupilumab for the Treatment of Patients with Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME). ClinicalTrials.gov identifier: NCT04183335. Updated February 17, 2022. Accessed September 28, 2022.

https://clinicaltrials.gov/ct2/show/NCT04183335?term=PRIME%2C+dupilumab&draw=2&rank=1

Videos

Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions. 

News 

FDA Approves Dupliumab for Prurigo Nodularis  

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, talks about how to treat tinea versicolor and how to keep it from coming back. 

Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses how to treat tinea versicolor.

Pointers With Dr Portela: How to Treat Tinea Versicolor 

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, visits the La Roche-Posay Thermal Treatment Center in France to discuss beneficial eczema treatments. 

In this week’s Pointers with Dr Portela, the 208SkinDoc travels to the La Roche-Posay Thermal Treatment Center. 

Pointers With Dr Portela: 5 Treatments That Fix Eczema at the La Roche-Posay Thermal Treatment Center

Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, talks about tinea versicolor.

In this week’s Pointers with Dr Portela, the 208SkinDoc talks what a “summer rash” is and prevention. 


Pointers With Portela: Tinea Versicolor

At the 2022 Winter Clinical Dermatology Conference, Ted Rosen, MD, professor of dermatology at Baylor College of Medicine and chief of dermatology at the Houston VA medical center in Houston, Texas, gave the presentation, "What's Hot and New in Infectious Disease?" Here he dives into the details of infectious disease and explains what some physicians may miss.

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Misconceptions, Pipeline, and Prevention of ID

Ted Rosen, MD, professor of dermatology at Baylor College of Medicine and chief of dermatology at the Houston VA medical center in Houston, Texas, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference. From ticks and scabies to COVID-19, he highlights many clinical pearls.

Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference. 

Inflamed Skin

Latest News

More News